Use of Exome Sequencing to Determine the Full Profile of Genetic Variants in the Fluoropyrimidine Pathway in Colorectal Cancer Patients Affected by Severe Toxicity

References

• Gray R , BarnwellJ , McConkeyC , HillsRK , WilliamsNS , KerrDJ . Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study . Lancet370 ( 9604 ), 2020 – 2029 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA , MayerRJ . Systemic therapy for colorectal cancer . N. Engl. J. Med.352 ( 5 ), 476 – 487 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Fernandez-Rozadilla C , CazierJB , MorenoVet al. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration . Pharmacogenomics J.13 ( 3 ), 209 – 217 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Mohelnikova-Duchonova B , MelicharB , SoucekP . FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy . World J. Gastroenterol.20 ( 30 ), 10316 – 10330 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Chua W , KhoPS , MooreMM , CharlesKA , ClarkeSJ . Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer . Crit. Rev. Oncol. Hematol.79 ( 3 ), 224 – 250 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Cortejoso L , García-GonzálezX , GarcíaMI , García-AlfonsoP , SanjurjoM , López-FernándezLA . Cost–effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines . Pharmacogenomics17 ( 9 ), 979 – 984 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Cortejoso L , GarcíaMI , García-AlfonsoPet al. [Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients] . Farm. Hosp.38 ( 4 ), 283 – 290 ( 2014 ).
   PubMedGoogle Scholar
• Rosmarin D , PallesC , PagnamentaAet al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS . Gut64 ( 1 ), 111 – 120 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Kadoyama K , MikiI , TamuraT , BrownJB , SakaedaT , OkunoY . Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations . Int. J. Med. Sci.9 ( 1 ), 33 – 39 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Thorn CF , MarshS , CarrilloMW , McLeodHL , KleinTE , AltmanRB . PharmGKB summary: fluoropyrimidine pathways . Pharmacogenet. Genomics21 ( 4 ), 237 – 242 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Caudle KE , ThornCF , KleinTEet al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing . Clin. Pharmacol. Ther.94 ( 6 ), 640 – 645 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Milano G . Highlight on DPYD gene polymorphisms and treatment by capecitabine (.) . Scand. J. Clin. Lab. Invest. Suppl.245 , S30 – S33 ( 2016 ).
   PubMedGoogle Scholar
• Saif MW , LeeAM , OfferSM , McConnellK , ReliasV , DiasioRB . A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach . Mayo Clin. Proc.89 ( 1 ), 131 – 136 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Etienne-Grimaldi M-C , BoyerJ-C , BeroudCet al. New advances in DPYD genotype and risk of severe toxicity under capecitabine . PLoS ONE12 ( 5 ), e0175998 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• García-González X , CortejosoL , GarcíaMI , GarcíaP , SanjurjoM , López-fernándezLA . Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer . Oncotarget6 ( 8 ), 6422 – 6430 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Schwab M , ZangerUM , MarxCet al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU toxicity study group . J. Clin. Oncol.26 ( 13 ), 2131 – 2138 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Jennings BA , LokeYK , SkinnerJet al. Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines . PLoS ONE8 ( 10 ), e78053 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Glimelius B , GarmoH , BerglundAet al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer . Pharmacogenomics J.11 ( 1 ), 61 – 71 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Strimpakos AS , SyrigosKN , SaifMW . Pharmacogenetics and biomarkers in colorectal cancer . Pharmacogenomics J.9 ( 3 ), 147 – 160 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Braun MS , RichmanSD , ThompsonLet al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial . J. Clin. Oncol.27 ( 33 ), 5519 – 5528 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Rosmarin D , PallesC , ChurchDet al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis . J. Clin. Oncol.32 ( 10 ), 1031 – 1039 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kalia M . Personalized oncology: recent advances and future challenges . Metabolism64 ( 3 ), S16 – S21 ( 2012 ).
   Google Scholar
• Zhang J , ChiodiniR , BadrA , ZhangG . The impact of next-generation sequencing on genomics . J. Genet. Genomics38 ( 3 ), 95 – 109 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Chan EY . Next-generation sequencing methods: impact of sequencing accuracy on SNP discovery . Methods Mol. Biol.578 , 95 – 111 ( 2009 ).
   PubMedGoogle Scholar
• Mizzi C , PetersB , MitropoulouCet al. Personalized pharmacogenomics profiling using whole-genome sequencing . Pharmacogenomics15 ( 9 ), 1223 – 1234 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Zhou Y , Ingelman-SundbergM , LauschkeV . Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects . Clin. Pharmacol. Ther. doi:10.1002/cpt.690 ( 2017 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Kumar P , HenikoffS , NgPC . Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm . Nat. Protoc.4 ( 7 ), 1073 – 1081 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Adzhubei IA , SchmidtS , PeshkinLet al. A method and server for predicting damaging missense mutations . Nat. Method.7 ( 4 ), 248 – 249 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Boige V , VincentM , AlexandrePet al. DPYD genotyping to predict adverse events following treatment with flourouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the petacc-8 randomized clinical trial . JAMA Oncol. doi:10.1001/jamaoncol.2015.5392 ( 2016 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Gross E , BusseB , RiemenschneiderMet al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients . PLoS ONE3 ( 12 ), e4003 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Toffoli G , GiodiniL , BuonadonnaAet al. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines . Int. J. cancer.137 ( 12 ), 2971 – 2980 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Gentile G , BotticelliA , LionettoLet al. Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction . Pharmacogenomics J.16 ( 4 ), 320 – 325 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Afzal S , JensenSA , VainerBet al. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer . Ann. Oncol.20 ( 10 ), 1660 – 1666 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Custodio A , Moreno-RubioJ , AparicioJet al. Pharmacogenetic predictors of outcome in patients with Stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy . Mol. Cancer Ther.13 ( 9 ), 2226 – 2237 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ding X , ChenW , FanH , ZhuB . Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy . Gene559 ( 1 ), 31 – 37 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Hwang IG , JiJH , KangJHet al. A multi-center, open-label, randomized Phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer . J. Geriatr. Oncol.8 ( 3 ), 170 – 175 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Gréen H , HasmatsJ , KupershmidtIet al. Using whole-exome sequencing to identify genetic markers for carboplatin and gemcitabine-induced toxicities . Clin. Cancer Res.22 ( 2 ), 366 – 373 ( 2016 ).
   PubMed Web of Science ®Google Scholar